Globus Medical shares rose 0.7% to $81.13 at the latest close. The filing offers a mixed picture alongside that small move: revenue grew 5.9% in the three months ended June 30, operating income more than doubled, and net income fell 25.3%.

The operating line improved sharply. Operating margin rose to 23.1% from 10.2%, even as sales reached $789.6 million from $745.3 million. Net margin went the other way, falling to 19.2% from 27.2%.

The biggest help came from the cost base, not from a sudden acceleration in demand. Globus said three-month cost of sales fell $7.3 million, with the comparison helped by a prior-year inventory step-up tied to Nevro that did not repeat.

"The $7.3 million, or 2.9%, decrease in cost of sales for the three months ended June 30, 2026 was primarily driven by Nevro amortization of inventory step up of $6.0 million in the prior-year period, with no comparable event in the current-year period."

Globus Medical, 10-Q, August 6, 2026

That is a real margin improvement, but part of the arithmetic is unusually specific: last year had a $6 million charge that this year did not. Selling, general and administrative expenses also fell 5.5%, driven mainly by lower employee-related expenses, and restructuring costs dropped sharply.

The bottom line remains the filing’s unresolved wrinkle. Other income increased by $5.9 million in the three months, primarily because of higher interest income, yet net income still declined by $51.2 million. Globus does not disclose the supplied cause of that gap.

"Other income/(expense) increased by $5.9 million, or 391.3%, primarily due to a $5.7 million increase in interest income."

Globus Medical, 10-Q, August 6, 2026

Interest income helped, but it did not determine the three-month period. The difference between operating income and net income means the sharp operating recovery did not flow through cleanly to earnings per share, which fell to $1.10 from $1.49.

The balance sheet adds another detail to the growth question. Inventory rose 5.0%, roughly in line with sales, but accounts receivable climbed 13.2%. Cash conversion improved, with free-cash-flow margin up 9.1 percentage points and capital-spending intensity lower, so the working-capital movements are not a standalone cash-flow verdict. They are still figures to reconcile with the sales pace.

Globus’s annual record supplies some context without resolving the current trade-off. Revenue rose 16.7% in 2025 and operating margin reached 16.3%. The latest report shows that margin can move quickly when employee expenses and restructuring charges change, even with sales growth in the mid-single digits.

The next quarterly report’s bridge from operating income to net income will clarify the factual gap left here, particularly the item or items behind the $51.2 million decline. For now, Globus kept more from each sale at the operating level, but the earnings line still found a way to keep less.

Source: Globus Medical’s 10-Q filed August 6, 2026, for the three months ended June 30, 2026.